Slideflow Labs
Angel
Slideflow Labs develops an AI platform for digital pathology that transforms H&E slides into quantitative cancer biomarkers.
Founded
2024Slideflow Labs develops an AI platform for digital pathology that transforms H&E slides into quantitative cancer biomarkers.
Slideflow Labs offers an AI platform for digital pathology that transforms standard H&E slides into quantitative cancer biomarkers. The platform runs locally inside hospital infrastructure as isolated containers, ensuring data privacy and security.
The company provides both an open-source deep learning framework for researchers and Slideflow Pro, a regulatory-grade deployment engine for clinical workflows. The platform integrates with existing pathology scanning infrastructure and returns results to physicians in minutes.
The digital pathology market is expanding rapidly as healthcare systems adopt AI-driven diagnostics to improve accuracy and efficiency. Slideflow Labs targets hospitals and pathology labs seeking to deploy digital biomarkers while maintaining data sovereignty.
The company is pursuing FDA regulatory clearance for its clinical-grade tools and plans to expand partnerships with biotech, pharmaceutical, and healthcare organizations. The growing demand for in-house AI diagnostics positions Slideflow Labs to capture share in the enterprise healthcare market.
Slideflow Labs differentiates itself through local deployment, allowing hospitals to maintain full control over patient data without sending slides to external cloud services. This addresses key concerns around data privacy, security, and regulatory compliance in healthcare.
The company also leverages a widely adopted open-source framework with over 100 peer-reviewed studies, providing credibility and a research community. The platform works with low-cost, locally available hardware, reducing the total cost of ownership compared to cloud-dependent competitors.
